The research programs at iTherX are focused on the area of
Hepatitis C.

We have used our laboratory research capability to make discoveries that can be the basis for novel proprietary products. These discoveries include cellular or viral genes whose functions contribute to the cause or pathophysiology of the disease, or proprietary functional assays to screen chemical libraries to obtain compounds with desirable drug - like properties. Optimized drug candidates are taken into preclinical toxicology studies to define doses safe to give to humans, followed by clinical proof of concept studies that show whether the compound has the potential to become an approved drug.

In addition, our pipeline also includes biologic therapies such as monoclonal antibodies.